BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 31303281)

  • 1. Effects of Food and Calcium Carbonate on the Pharmacokinetics of Lusutrombopag, a Novel Thrombopoietin Receptor Agonist.
    Katsube T; Wajima T; Fukuhara T; Kano T
    Clin Ther; 2019 Sep; 41(9):1747-1754.e2. PubMed ID: 31303281
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of drug-drug interaction of lusutrombopag, a thrombopoietin receptor agonist, via metabolic enzymes and transporters.
    Katsube T; Inoue Y; Fukuhara T; Kano T; Wajima T
    Eur J Clin Pharmacol; 2020 Dec; 76(12):1659-1665. PubMed ID: 32666123
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of food and antacids on the pharmacokinetics of eltrombopag in healthy adult subjects: two single-dose, open-label, randomized-sequence, crossover studies.
    Williams DD; Peng B; Bailey CK; Wire MB; Deng Y; Park JW; Collins DA; Kapsi SG; Jenkins JM
    Clin Ther; 2009 Apr; 31(4):764-76. PubMed ID: 19446149
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of food intake on the pharmacokinetic properties of mirabegron oral controlled-absorption system: a single-dose, randomized, crossover study in healthy adults.
    Lee J; Zhang W; Moy S; Kowalski D; Kerbusch V; van Gelderen M; Sawamoto T; Grunenberg N; Keirns J
    Clin Ther; 2013 Mar; 35(3):333-41. PubMed ID: 23497763
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetic/Pharmacodynamic Modelling and Simulation of Lusutrombopag, a Novel Thrombopoietin Receptor Agonist, for the Treatment of Thrombocytopenia in Patients with Chronic Liver Disease Undergoing Invasive Procedures.
    Katsube T; Shimizu R; Fukuhara T; Kano T; Wajima T
    Clin Pharmacokinet; 2019 Nov; 58(11):1469-1482. PubMed ID: 31055790
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized, open-label, 5-period, balanced crossover study to evaluate the relative bioavailability of eltrombopag powder for oral suspension (PfOS) and tablet formulations and the effect of a high-calcium meal on eltrombopag pharmacokinetics when administered with or 2 hours before or after PfOS.
    Wire MB; Bruce J; Gauvin J; Pendry CJ; McGuire S; Qian Y; Brainsky A
    Clin Ther; 2012 Mar; 34(3):699-709. PubMed ID: 22336488
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of Food Intake on the Relative Bioavailability of Amifampridine Phosphate Salt in Healthy Adults.
    Haroldsen PE; Musson DG; Hanson B; Quartel A; O'Neill CA
    Clin Ther; 2015 Jul; 37(7):1555-63. PubMed ID: 26101174
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Population Pharmacokinetic and Pharmacodynamic Modeling of Lusutrombopag, a Newly Developed Oral Thrombopoietin Receptor Agonist, in Healthy Subjects.
    Katsube T; Ishibashi T; Kano T; Wajima T
    Clin Pharmacokinet; 2016 Nov; 55(11):1423-1433. PubMed ID: 27209291
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics of a New Amphetamine Extended-release Oral Liquid Suspension Under Fasted and Fed Conditions in Healthy Adults: A Randomized, Open-label, Single-dose, 3-treatment Study.
    Sikes C; Stark JG; McMahen R; Engelking D
    Clin Ther; 2017 Dec; 39(12):2389-2398. PubMed ID: 29174216
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetic Assessment and Treatment Effect of Lusutrombopag in Child-Pugh Class C Patients: Review of Patient Data from Two Clinical Studies and Post-Marketing Surveillance.
    Flamm SL; Peck-Radosavljevic M; Fukuhara T; Bentley R; Katsube T; Ochiai T; Kano T; Tsukimura E; Sasaki R; Osaki Y
    Adv Ther; 2022 Sep; 39(9):4285-4298. PubMed ID: 35904722
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relative bioavailability and effects of a high fat meal on single dose cilostazol pharmacokinetics.
    Bramer SL; Forbes WP
    Clin Pharmacokinet; 1999; 37 Suppl 2():13-23. PubMed ID: 10702883
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomized controlled trial of lusutrombopag in Japanese patients with chronic liver disease undergoing radiofrequency ablation.
    Tateishi R; Seike M; Kudo M; Tamai H; Kawazoe S; Katsube T; Ochiai T; Fukuhara T; Kano T; Tanaka K; Kurokawa M; Yamamoto K; Osaki Y; Izumi N; Imawari M
    J Gastroenterol; 2019 Feb; 54(2):171-181. PubMed ID: 30105510
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Single-dose pharmacokinetics of 2 or 3 tablets of biphasic immediate-release/extended-release hydrocodone bitartrate/acetaminophen (MNK-155) under fed and fasted conditions: two randomized open-label trials.
    Devarakonda K; Kostenbader K; Giuliani MJ; Young JL
    BMC Pharmacol Toxicol; 2015 Nov; 16():31. PubMed ID: 26614499
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of Food on the Pharmacokinetic and Pharmacodynamic Profiles of Hetrombopag in Healthy Volunteers.
    Wang Z; Chen X; Li A; Chen L; Wang Y; Zheng L
    Clin Ther; 2020 Dec; 42(12):2280-2288. PubMed ID: 33109386
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Investigation of the effect of food and omeprazole on the relative bioavailability of a single oral dose of 240 mg faldaprevir, a selective inhibitor of HCV NS3/4 protease, in an open-label, randomized, three-way cross-over trial in healthy participants.
    Wu J; Gießmann T; Lang B; Elgadi M; Huang F
    J Pharm Pharmacol; 2016 Apr; 68(4):459-66. PubMed ID: 27019158
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential pharmacokinetics of diclofenac potassium for oral solution vs immediate-release tablets from a randomized trial: effect of fed and fasting conditions.
    Chen C; Bujanover S; Kareht S; Rapoport AM
    Headache; 2015 Feb; 55(2):265-75. PubMed ID: 25546369
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dose proportionality and the effects of food on bioavailability of an immediate-release oxycodone hydrochloride tablet designed to discourage tampering and its relative bioavailability compared with a marketed oxycodone tablet under fed conditions: a single-dose, randomized, open-label, 5-way crossover study in healthy volunteers.
    Bass A; Stark JG; Pixton GC; Sommerville KW; Zamora CA; Leibowitz M; Rolleri R
    Clin Ther; 2012 Jul; 34(7):1601-12. PubMed ID: 22717418
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I crossover study of DNA-protein kinase inhibitor peposertib in healthy volunteers: Effect of food and pharmacokinetics of an oral suspension.
    Becker A; Krebs-Brown A; Vetter C; Reuter T; Rodriguez-Gutierrez A; You X; Lissy M
    Clin Transl Sci; 2023 Dec; 16(12):2628-2639. PubMed ID: 37905356
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics of dolutegravir when administered with mineral supplements in healthy adult subjects.
    Song I; Borland J; Arya N; Wynne B; Piscitelli S
    J Clin Pharmacol; 2015 May; 55(5):490-6. PubMed ID: 25449994
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of Food on the Pharmacokinetic Properties of Surufatinib: A Phase I, Single-dose, Randomized, Open-label Crossover Study in Healthy Subjects.
    Qian H; Wu X; Chen Q; Li T; Wang W; Jia J; Yu C; Li K; Sai Y; Su W; Liu Y
    Clin Ther; 2020 Sep; 42(9):1778-1786. PubMed ID: 32800383
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.